MATINAS BIOPHARMA HOLDINGS, INC.: operating cash flow
Operating cash flow for MATINAS BIOPHARMA HOLDINGS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All MATINAS BIOPHARMA HOLDINGS, INC. financial histories
What this measure means
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
Exact concept: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2015-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -7,011,000 | USD | 2026-03-31 | 10-K · 0001493152-26-014132 |
| 2024-01-01 | 2024-12-31 | -15,885,000 | USD | 2026-03-31 | 10-K · 0001493152-26-014132 |
| 2023-01-01 | 2023-12-31 | -15,278,000 | USD | 2025-04-15 | 10-K · 0001641172-25-004882 |
| 2022-01-01 | 2022-12-31 | -19,156,000 | USD | 2024-03-27 | 10-K · 0001493152-24-011493 |
| 2021-01-01 | 2021-12-31 | -15,223,000 | USD | 2023-03-15 | 10-K · 0001493152-23-007726 |
| 2020-01-01 | 2020-12-31 | -17,367,836 | USD | 2022-03-11 | 10-K/A · 0001493152-22-006614 |
| 2019-01-01 | 2019-12-31 | -14,092,066 | USD | 2021-03-29 | 10-K · 0001493152-21-006979 |
| 2018-01-01 | 2018-12-31 | -10,321,209 | USD | 2020-03-09 | 10-K · 0001493152-20-003558 |
| 2017-01-01 | 2017-12-31 | -11,459,616 | USD | 2019-04-01 | 10-K · 0001493152-19-004560 |
| 2016-01-01 | 2016-12-31 | -6,118,723 | USD | 2018-03-16 | 10-K · 0001493152-18-003518 |
| 2015-01-01 | 2015-12-31 | -7,814,403 | USD | 2018-03-16 | 10-K · 0001493152-18-003518 |
Related financial histories
- MATINAS BIOPHARMA HOLDINGS, INC.: total assets
- MATINAS BIOPHARMA HOLDINGS, INC.: total liabilities
- MATINAS BIOPHARMA HOLDINGS, INC.: stockholders equity
- MATINAS BIOPHARMA HOLDINGS, INC.: cash and cash equivalents
- MATINAS BIOPHARMA HOLDINGS, INC.: net income or loss
- MATINAS BIOPHARMA HOLDINGS, INC.: capital expenditure payments
- MATINAS BIOPHARMA HOLDINGS, INC.: revenue
- MATINAS BIOPHARMA HOLDINGS, INC.: contract revenue excluding tax
- MATINAS BIOPHARMA HOLDINGS, INC.: financing cash flow
- MATINAS BIOPHARMA HOLDINGS, INC.: investing cash flow
- MATINAS BIOPHARMA HOLDINGS, INC.: retained earnings or deficit
- MATINAS BIOPHARMA HOLDINGS, INC.: basic weighted-average shares
- MATINAS BIOPHARMA HOLDINGS, INC.: diluted weighted-average shares
- MATINAS BIOPHARMA HOLDINGS, INC.: basic earnings per share
- MATINAS BIOPHARMA HOLDINGS, INC.: diluted earnings per share
- MATINAS BIOPHARMA HOLDINGS, INC.: income tax expense or benefit
- MATINAS BIOPHARMA HOLDINGS, INC.: net property, plant and equipment
- MATINAS BIOPHARMA HOLDINGS, INC.: share-based compensation expense
- MATINAS BIOPHARMA HOLDINGS, INC.: operating income or loss
- MATINAS BIOPHARMA HOLDINGS, INC.: current assets
- MATINAS BIOPHARMA HOLDINGS, INC.: current liabilities
- MATINAS BIOPHARMA HOLDINGS, INC.: current accounts payable
- MATINAS BIOPHARMA HOLDINGS, INC.: goodwill carrying amount
- MATINAS BIOPHARMA HOLDINGS, INC.: operating expenses
- MATINAS BIOPHARMA HOLDINGS, INC.: research and development expense
Inspect the source
- Entity
- MATINAS BIOPHARMA HOLDINGS, INC. / CIK 0001582554
- Captured
- 2026-09-20T09:22:54.236Z
- SEC response SHA-256
218993fbdcae524fc0c120e888a258d2be15df63a5b4cfc0f198760659dede1e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001582554.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))